Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation?

Nature Clinical Practice Urology volume 3, pages 258–259 (2006)Cite this article

boxed-textVargas et al. (2005) Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 63: 1474–1482

Men at >15% risk of lymph-node metastasis should not routinely forgo pelvic radiotherapy to iliac lymph nodes, unless individual patient factors or the results of the RTOG 94-13 study suggest otherwise

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bolla M et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300

    Article  CAS  Google Scholar 

  2. Pilepich MV et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15: 1013–1021

    Article  CAS  Google Scholar 

  3. Pilepich MV et al. (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616–623

    Article  CAS  Google Scholar 

  4. Roach M III et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904–1911

    Article  Google Scholar 

  5. Roach M III et al. (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28: 33–37

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Professor of Urology,

    Ganesh S Palapattu & Edward M Messing

  2. the Chair of the Department of Urology, WW Scott Professor of Urology, and a Professor of Oncology and Pathology, at the James P Wilmot Cancer Center, University of Rochester School of Medicine, NY, USA

    Ganesh S Palapattu & Edward M Messing

Authors
  1. Ganesh S Palapattu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward M Messing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward M Messing.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palapattu, G., Messing, E. Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation?. Nat Rev Urol 3, 258–259 (2006). https://doi.org/10.1038/ncpuro0463

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0463

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing